In fiscal 2026, which ended Mar 31, 2026, Elite Pharmaceuticals, Inc. generated $23.7 million of cash from operations, up 218.5% from the year before. It spent $925,626 on capital expenditures. That left free cash flow of $22.8 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jun 30, 2026
|
FY 2026
Mar 31, 2026
|
FY 2025
Mar 31, 2025
|
FY 2024
Mar 31, 2024
|
FY 2023
Mar 31, 2023
|
FY 2022
Mar 31, 2022
|
FY 2021
Mar 31, 2021
|
FY 2020
Mar 31, 2020
|
FY 2019
Mar 31, 2019
|
FY 2018
Mar 31, 2018
|
FY 2012
Mar 31, 2013
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Depreciation and amortization |
1
-11.1%
|
1
-12.6%
|
1
-7.1%
|
1
+3.4%
|
1
+5.7%
|
1
-8.0%
|
1
-0.5%
|
1
+5.0%
|
1
+26.1%
|
1
+39.4%
|
0
-12.6%
|
| Stock-based compensation |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
-31.5%
|
| Operating cash flow |
19
-0.2%
|
24
+218.5%
|
7
+330.5%
|
-3
-196.9%
|
3
-48.7%
|
7
+103.8%
|
3
+278.0%
|
-2
+73.6%
|
-7
-41.2%
|
-5
|
-2
-393.1%
|
| Investing | |||||||||||
| Capital expenditures |
2
+42.4%
|
1
-43.0%
|
2
+100.7%
|
1
-85.9%
|
6
|
—
|
—
|
—
|
—
|
—
|
—
|
| Investing cash flow |
-2
-58.8%
|
-1
+61.4%
|
-2
-196.4%
|
-1
+85.9%
|
-6
-1050.6%
|
-0
-89.7%
|
-0
-651.8%
|
-0
-110.6%
|
0
+220.4%
|
-0
|
-0
+70.8%
|
| Financing | |||||||||||
| Debt repaid |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
-61.4%
|
—
|
| Short-term debt repaid |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1
+36.4%
|
0
-53.0%
|
| Financing cash flow |
-0
+93.6%
|
-4
-423.4%
|
-1
-124.7%
|
3
+96.2%
|
2
+355.2%
|
-1
+23.3%
|
-1
-226.1%
|
1
-56.0%
|
2
-6.2%
|
2
|
2
+1838.8%
|
| Change in cash | |||||||||||
| Net change in cash |
17
+29.0%
|
19
+337.3%
|
4
+699.5%
|
-1
-1.4%
|
-1
|
—
|
—
|
-1
+76.7%
|
-5
|
—
|
—
|
| Free cash flow |
18
-2.8%
|
23
+291.4%
|
6
+244.2%
|
-4
-68.7%
|
-2
|
—
|
—
|
—
|
—
|
—
|
—
|
| Per share | |||||||||||
| Free cash flow per share |
0.02
-10.1%
|
0.02
+267.3%
|
0.01
+238.1%
|
-0.00
-67.0%
|
-0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
| Ratios | |||||||||||
| Free cash flow margin |
12.43%
|
15.33%
|
6.94%
|
-7.14%
|
-7.02%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Capital expenditures to revenue |
1.08%
|
0.62%
|
1.93%
|
1.43%
|
16.80%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Stock-based compensation to revenue |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4.29%
|
| Cash conversion |
0.34x
|
0.53x
|
—
|
-0.16x
|
0.94x
|
0.73x
|
0.63x
|
—
|
—
|
—
|
-1.31x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTP (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NJ
- Headquarters
- Northvale, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1053369
- Former names
- ELITE PHARMACEUTICALS INC /DE/ (until Feb 8, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.